Ambit Biosciences Corp (AMBI) 15.60 $AMBI
Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society Of Hematology (ASH)
PR Newswire - Thu Dec 04, 3:40PM CST
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, and Daiichi Sankyo, Inc. today announced acceptance of three abstracts with preliminary data highlighting Ambit's lead drug candidate, quizartinib. Presentations of the final data will be made during the 56th ASH Annual Meeting at the Moscone Center in San Francisco, CA on December 6-9, 2014. Oral presentations include the following:
AMBI: 15.60 (+0.26)
Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dnbkc/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh - JW Pharmaceutical - Karyopharm - Kyowa Hakko Kirin - Les Laboratoires Servier - MacroGenics - Merck & Co - Millennium - Novartis - Piramal - Plexxikon - Polaris - Seattle Genetics - SpectraMab - Sunesis - Synta - Targa - Tolero - Verastem, For more information visit http://www.researchandmarkets.com/research/7d...tory_acute
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), AMBI: 15.60 (+0.26), GSK: 47.94 (+1.99), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 34.09 (+0.10), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), CTIC: 2.23 (-0.02), GSK: 47.94 (+1.99), VSTM: 7.93 (-0.44), SNTA: 2.29 (-0.03), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), AMBI: 15.60 (+0.26), CELGZ: 3.17 (-0.04), KPTI: 27.12 (-0.13), NVS: 102.20 (-0.17)
Merger Arbitrage Mondays - November 17, 2014
Asif Suria - at Seeking Alpha - Mon Nov 17, 12:52PM CST
Merger Activity decreased last week with two new mergers announced and four deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
ATHL: 58.40 (unch), ECA: 14.07 (+0.37), BBT: 38.28 (-0.04), OILT: 44.69 (+0.29), AMBI: 15.60 (+0.26), MOVE: 20.95 (-0.03), NWS: 16.41 (+0.05), SUSQ: 13.48 (+0.01), EPD: 34.44 (+0.19)
Daiichi Sankyo and Ambit Announce Results of Tender Offer
PR Newswire - Mon Nov 10, 6:37PM CST
Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the results of Daiichi Sankyo's tender offer to purchase all of the outstanding shares of Ambit Biosciences' common stock for $15.00 per share plus one non-transferable contingent value right per share, which will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones relating to quizartinib. The tender offer is being effected by Daiichi Sankyo's subsidiary, Charge Acquisition Corp.
AMBI: 15.60 (+0.26)
Ambit Announces Expiration of Hart-Scott-Rodino Waiting Period
PR Newswire - Tue Oct 28, 5:30PM CDT
Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"
in connection with Daiichi Sankyo's previously announced tender offer for all of the outstanding common stock of Ambit Biosciences (hereinafter, the Tender Offer).
AMBI: 15.60 (+0.26)
Ciclofilin Pharmaceuticals Appoints Stephen F. Keane as Senior VP of Corporate Development
GlobeNewswire - Mon Oct 27, 10:07AM CDT
Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company" , a developer of broad spectrum antiviral medications, announced today the appointment of Stephen F. Keane as Senior Vice President of Corporate Development. In this role, Mr. Keane will be responsible for structuring, negotiating and executing successful strategic alliances and co-development agreements, as well as providing general corporate development leadership to the Company.
MRK: 58.81 (-0.07), DNDN: 0.13 (-0.02), AMBI: 15.60 (+0.26)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Ambit Biosciences Corporation of Class Action Challenging the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd. -- AMBI
GlobeNewswire - Mon Oct 20, 9:29AM CDT
Levi & Korsinsky notifies investors of Ambit Biosciences Corporation ("Ambit" or "the Company" (Nasdaq:AMBI) of claims of breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. A complaint was filed in Delaware state court.
AMBI: 15.60 (+0.26)
Announcement Regarding Submission of Tender Offer for Shares in Ambit Biosciences Corporation
PR Newswire - Tue Oct 14, 3:43PM CDT
On Friday October 10, U.S. Eastern Time, Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568), through its wholly-owned U.S. subsidiary, Charge Acquisition Corp., launched a tender offer to acquire the outstanding common stock of Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) for $15.00 per share plus one non-transferable contingent value right per share that will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones regarding quizartinib (hereinafter, the Tender Offer). Failing any extension to the offer period, the offer is due to expire at 5:00 P.M. U.S. Eastern Time on November 10, 2014.
AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of Ambit Biosciences Corporation in Connection With the Sale of the Company to Daiichi Sankyo Company, Ltd.
Business Wire - Tue Oct 14, 9:16AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Ambit Biosciences Corporation (NasdaqGM:AMBI) ("Ambit Biosciences" in connection with the sale of the Company to Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Ambit Biosciences Corporation in Connection with the Sale of the Company
Business Wire - Fri Oct 10, 8:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company" (Nasdaq: AMBI) relating to the proposed acquisition by Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc.
PR Newswire - Tue Oct 07, 5:31PM CDT
AcelRx Pharmaceuticals, Inc.
ACRX: 7.29 (-0.06), ATHL: 58.40 (unch), LPDX: 5.24 (-0.01), TIBX: 24.03 (+0.03), AMBI: 15.60 (+0.26), SMPL: 17.70 (+0.20)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of Ambit Biosciences Corporation in Connection With the Sale of the Company to Daiichi Sankyo Company, Ltd. - AMBI
PR Newswire - Tue Oct 07, 12:05PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Ambit Biosciences Corporation (NasdaqGM: AMBI) ("Ambit Biosciences" in connection with the sale of the Company to Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
at The Street - Tue Oct 07, 10:39AM CDT
For the past three months, small-cap biotech stocks are underperforming the broader market.
MNOV: 3.62 (-0.56), ESPR: 67.13 (-0.33), ADHD: 6.92 (+0.73), SNSS: 2.28 (+0.01), AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Ambit Biosciences Corporation And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Oct 06, 3:58PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company" (Nasdaq: AMBI) relating to the proposed buyout of the Company by Daiichi Sankyo Company, Ltd. ("Daiichi Sankyo" .
AMBI: 15.60 (+0.26)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Ambit Biosciences Corporation Concerning the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd.
Business Wire - Wed Oct 01, 3:29PM CDT
Levi & Korsinsky is investigating the Board of Directors of Ambit Biosciences Corporation ("Ambit" or "the Company" (NasdaqGM: AMBI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
Ambit Biosciences Corporation Stockholders Encouraged to Contact Securities Law Firm about Takeover
PR Newswire - Wed Oct 01, 2:23PM CDT
Securities lawyers at Dunnam & Dunnam are investigating the board of Ambit Biosciences Corporation (NASDAQ: AMBI) in connection with a buyout for only $15 per share. Concerned AMBI investors are encouraged to contact attorney Hamilton Lindley by clicking here.
AMBI: 15.60 (+0.26)
Ryan & Maniskas, LLP Announces Investigation of Ambit Biosciences Corporation
PR Newswire - Wed Oct 01, 10:48AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Ambit Biosciences Corporation ("Ambit" or the "Company" (NASDAQ: AMBI) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Daiichi Sankyo Company, Ltd. in a transaction valued at approximately $315 million.
AMBI: 15.60 (+0.26)
Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society Of Hematology (ASH)
PR Newswire - Thu Dec 04, 3:40PM CST
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, and Daiichi Sankyo, Inc. today announced acceptance of three abstracts with preliminary data highlighting Ambit's lead drug candidate, quizartinib. Presentations of the final data will be made during the 56th ASH Annual Meeting at the Moscone Center in San Francisco, CA on December 6-9, 2014. Oral presentations include the following:
AMBI: 15.60 (+0.26)
Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dnbkc/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh - JW Pharmaceutical - Karyopharm - Kyowa Hakko Kirin - Les Laboratoires Servier - MacroGenics - Merck & Co - Millennium - Novartis - Piramal - Plexxikon - Polaris - Seattle Genetics - SpectraMab - Sunesis - Synta - Targa - Tolero - Verastem, For more information visit http://www.researchandmarkets.com/research/7d...tory_acute
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), AMBI: 15.60 (+0.26), GSK: 47.94 (+1.99), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 34.09 (+0.10), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), CTIC: 2.23 (-0.02), GSK: 47.94 (+1.99), VSTM: 7.93 (-0.44), SNTA: 2.29 (-0.03), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), AMBI: 15.60 (+0.26), CELGZ: 3.17 (-0.04), KPTI: 27.12 (-0.13), NVS: 102.20 (-0.17)
Merger Arbitrage Mondays - November 17, 2014
Asif Suria - at Seeking Alpha - Mon Nov 17, 12:52PM CST
Merger Activity decreased last week with two new mergers announced and four deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
ATHL: 58.40 (unch), ECA: 14.07 (+0.37), BBT: 38.28 (-0.04), OILT: 44.69 (+0.29), AMBI: 15.60 (+0.26), MOVE: 20.95 (-0.03), NWS: 16.41 (+0.05), SUSQ: 13.48 (+0.01), EPD: 34.44 (+0.19)
Daiichi Sankyo and Ambit Announce Results of Tender Offer
PR Newswire - Mon Nov 10, 6:37PM CST
Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the results of Daiichi Sankyo's tender offer to purchase all of the outstanding shares of Ambit Biosciences' common stock for $15.00 per share plus one non-transferable contingent value right per share, which will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones relating to quizartinib. The tender offer is being effected by Daiichi Sankyo's subsidiary, Charge Acquisition Corp.
AMBI: 15.60 (+0.26)
Ambit Announces Expiration of Hart-Scott-Rodino Waiting Period
PR Newswire - Tue Oct 28, 5:30PM CDT
Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"
in connection with Daiichi Sankyo's previously announced tender offer for all of the outstanding common stock of Ambit Biosciences (hereinafter, the Tender Offer). AMBI: 15.60 (+0.26)
Ciclofilin Pharmaceuticals Appoints Stephen F. Keane as Senior VP of Corporate Development
GlobeNewswire - Mon Oct 27, 10:07AM CDT
Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"
, a developer of broad spectrum antiviral medications, announced today the appointment of Stephen F. Keane as Senior Vice President of Corporate Development. In this role, Mr. Keane will be responsible for structuring, negotiating and executing successful strategic alliances and co-development agreements, as well as providing general corporate development leadership to the Company. MRK: 58.81 (-0.07), DNDN: 0.13 (-0.02), AMBI: 15.60 (+0.26)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Ambit Biosciences Corporation of Class Action Challenging the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd. -- AMBI
GlobeNewswire - Mon Oct 20, 9:29AM CDT
Levi & Korsinsky notifies investors of Ambit Biosciences Corporation ("Ambit" or "the Company"
(Nasdaq:AMBI) of claims of breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. A complaint was filed in Delaware state court. AMBI: 15.60 (+0.26)
Announcement Regarding Submission of Tender Offer for Shares in Ambit Biosciences Corporation
PR Newswire - Tue Oct 14, 3:43PM CDT
On Friday October 10, U.S. Eastern Time, Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568), through its wholly-owned U.S. subsidiary, Charge Acquisition Corp., launched a tender offer to acquire the outstanding common stock of Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) for $15.00 per share plus one non-transferable contingent value right per share that will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones regarding quizartinib (hereinafter, the Tender Offer). Failing any extension to the offer period, the offer is due to expire at 5:00 P.M. U.S. Eastern Time on November 10, 2014.
AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of Ambit Biosciences Corporation in Connection With the Sale of the Company to Daiichi Sankyo Company, Ltd.
Business Wire - Tue Oct 14, 9:16AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Ambit Biosciences Corporation (NasdaqGM:AMBI) ("Ambit Biosciences"
in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Ambit Biosciences Corporation in Connection with the Sale of the Company
Business Wire - Fri Oct 10, 8:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company"
(Nasdaq: AMBI) relating to the proposed acquisition by Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc.
PR Newswire - Tue Oct 07, 5:31PM CDT
AcelRx Pharmaceuticals, Inc.
ACRX: 7.29 (-0.06), ATHL: 58.40 (unch), LPDX: 5.24 (-0.01), TIBX: 24.03 (+0.03), AMBI: 15.60 (+0.26), SMPL: 17.70 (+0.20)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of Ambit Biosciences Corporation in Connection With the Sale of the Company to Daiichi Sankyo Company, Ltd. - AMBI
PR Newswire - Tue Oct 07, 12:05PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Ambit Biosciences Corporation (NasdaqGM: AMBI) ("Ambit Biosciences"
in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
at The Street - Tue Oct 07, 10:39AM CDT
For the past three months, small-cap biotech stocks are underperforming the broader market.
MNOV: 3.62 (-0.56), ESPR: 67.13 (-0.33), ADHD: 6.92 (+0.73), SNSS: 2.28 (+0.01), AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Ambit Biosciences Corporation And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Oct 06, 3:58PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company"
(Nasdaq: AMBI) relating to the proposed buyout of the Company by Daiichi Sankyo Company, Ltd. ("Daiichi Sankyo" . AMBI: 15.60 (+0.26)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Ambit Biosciences Corporation Concerning the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd.
Business Wire - Wed Oct 01, 3:29PM CDT
Levi & Korsinsky is investigating the Board of Directors of Ambit Biosciences Corporation ("Ambit" or "the Company"
(NasdaqGM: AMBI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
Ambit Biosciences Corporation Stockholders Encouraged to Contact Securities Law Firm about Takeover
PR Newswire - Wed Oct 01, 2:23PM CDT
Securities lawyers at Dunnam & Dunnam are investigating the board of Ambit Biosciences Corporation (NASDAQ: AMBI) in connection with a buyout for only $15 per share. Concerned AMBI investors are encouraged to contact attorney Hamilton Lindley by clicking here.
AMBI: 15.60 (+0.26)
Ryan & Maniskas, LLP Announces Investigation of Ambit Biosciences Corporation
PR Newswire - Wed Oct 01, 10:48AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Ambit Biosciences Corporation ("Ambit" or the "Company"
(NASDAQ: AMBI) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Daiichi Sankyo Company, Ltd. in a transaction valued at approximately $315 million. AMBI: 15.60 (+0.26)
